RecruitingNCT06334835

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.

Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood


Sponsor

IRCCS SYNLAB SDN

Enrollment

20 participants

Start Date

Apr 30, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Long non-coding RNAs (lncRNAs) are a class of biomarkers of crescent interest in the hematologic and oncologic field. They do not encode proteins and can alter gene expression by acting on different steps of regulation, including DNA methylation and chromatin structure. Recent data identified recurrent somatic alterations in genes involved in DNA methylation and post-translational histone modifications in T-ALL, suggesting that epigenetic homeostasis is critically required in restraining tumor development in the T-cell lineage. Further, recent studies showed that the expression levels of specific lncRNAs correlate with the prognosis of patients with Acute Lymphoblastic Leukemia of T-cells (T-ALL). The objectives of this research project are to identify T-ALL-specific lncRNAs to be used as new diagnostic and prognostic biomarkers of disease and to explore their role on chromatin reorganization and transcriptional regulation that may lead to the onset and progression of T-ALL.


Eligibility

Min Age: 1 YearMax Age: 18 Years

Inclusion Criteria2

  • Patients with a diagnosis of T-ALL 1-18 years aged of both sexes;
  • Presence of leukemic cells in peripheral blood of recruited patients.

Exclusion Criteria2

  • Patients who refuse to participate in the study;
  • Patients not falling in the age group mentioned above

Interventions

DIAGNOSTIC_TESTlncRNA signature analyses

Evaluation of a signature of identified lncRNA in a cohort of childhood T-ALL patients in comparison with healthy subjects.


Locations(1)

Irccs Synlab Sdn

Naples, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06334835


Related Trials